You searched for "intracameral"

625 results found

Globes in space: What would happen to our globes on the globe of Mars?

Many films have been made regarding life on alternative planets. With the Mars One mission approaching in 2023, there are high expectations regarding future interplanetary travel. The authors provide an ophthalmology perspective on what could happen to our eyes if...

Ocular manifestations of multiple sclerosis: an overview

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS), in which there is dissemination of lesions in time (two or more clinical events) and space (multiple lesions seen on brain and spinal imaging). The pathophysiology...

What’s new in glaucoma? Clinical trials drive practice changes, surgical advancements gather pace

Rod McNeil reviews the latest developments in the treatment of glaucoma in the UK. Primary open-angle glaucoma (POAG), which accounts for over two-thirds of all glaucoma cases, has an estimated UK prevalence in 2017 of approximately 2% of people over...

Patients blinded by stem cells! How safe are they really?

Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Patients blinded by stem cells! How safe are they really? Ever since the successful results following...

Effect of minor trauma in eyes with previously undiagnosed angioid streaks

Angioid streaks (AS) may be associated with pseudoxanthoma elasticum (PXE), Paget’s disease, haemoglobulinopathies, Ehlers-Danlos Syndrome or abetalipoproteinaemia. Histopathology showed retinal pigment epithelium (RPE) and choriocapillaris loss, elastic fibre degeneration, calcium deposition, active choroidal neovascular membrane (CNVM) and vascular endothelial growth...

Eye Surgery in Hot Climates (Fourth Edition)

The Fourth Edition of Eye Surgery in Hot Climates by William Dean and John Sandford-Smith has made a debut at a time when there is a surge of interest in global ophthalmology amongst novices and experts alike. Both authors have...

Intravitreal Ziv-Aflibercept: safety analysis

Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...

G-CSF intravitreal injections for NAION: a pilot study

In rodent models with anterior ischemic optic neuropathy (AION), granulocyte colony-stimulating factor (G-CSF) confers a neuroprotective effect on retinal ganglion cells (RGCs) via anti-apoptotic and anti-inflammatory processes. This prospective study investigated the efficacy of intravitreal injection of G-CSF for the...

Optic nerve swelling – your survival guide (part 2)

In this second article we will discuss bilateral optic nerve swelling, its aetiology, various investigations and possible treatments. We will also discuss various protocols used in the management of suspected optic nerve swelling cases. (Part one of this topic available...

My Top Five: Red flag presentations all resident doctors must know

Ophthalmic emergencies are time-critical situations where delays in recognition or management can lead to permanent vision loss [1]. For resident doctors and medical students, identifying these red flags can be daunting, especially given the complexity of the eye and its...

Insects, swelling and sight loss: a case of orbital inflammatory syndrome

Despite being the most common cause of painful orbital mass in adults and the third most common orbital disease, orbital inflammatory syndrome still proves to be a difficult ocular condition to diagnose, treat, and manage. A 41-year-old lady presented to...

ROP ocular outcomes after Bevacizumab treatment

The relationship between refractive outcomes and biometric parameters were evaluated following intravitreal Bevacizumab (IVB) monotherapy. Sixty-three infants were grouped into 1) infants treated with VB monotherapy for ROP (six with zone 1 and eight with posterior zone II retinopathy of...